EA 230

Drug Profile

EA 230

Alternative Names: EA-230; Peptide 46; Peptide EA 230

Latest Information Update: 27 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Exponential Biotherapies
  • Class Anti-inflammatories; Antiseptics; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Renal failure

Most Recent Events

  • 17 Jul 2016 Phase-II/III clinical trials in Renal failure (Prevention) in Netherlands (IV) (EudraCT2014-002481-78)
  • 07 Oct 2014 Exponential Biotherapies initiates enrolment in a phase I trial for Renal failure (Prevention, In volunteers) in Netherlands (EudraCT2014-002481-78)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top